Skip to content

A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer

A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220307
Enrollment
Unknown
Registered
2006-10-06
Start date
2006-10-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: - >= 18 years of age, adult patients - documented colon carcinoma - not a candidate for (neo) adjuvant radiotherapy - curative surgery not less than 4 and not more than 8 weeks prior to study randomization. Exclusion criteria: - evidence of metastatic disease - previous anti-angiogenic treatment for any malignancy -previous cytotoxic chemotherapy, radiotherapy, or immunotherapy for colon cancer - pregnant or lactating women - fertile men, or women of childbearing potential, not using adequate contraception - major surgical procedures, open biopsy, or significant traumatic injury, within 28 days prior to study treatment start - current or recent treatment (within 28 days prior to randomization) with another investigational drug, or participation in another investigational study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Disease -free survival,

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026